Press releases

Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the...

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City. Mike Mahoney, chairman and chief executive...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, 2017 in Boston. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity Growth Conference on August 9, 2017 in Boston. Boston Scientific investor relations representatives,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at

Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman...

Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the...

Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating...